# EDGAR Filing Document

**Accession Number:** 0001231457
**File Stem:** 0001493152-26-029607
**Filing Date:** 2026-6
**Character Count:** 5822
**Document Hash:** ef461a2dbc6b51f3cdf289cc359af7af
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-029607.hdr.sgml**: 20260622

**ACCESSION NUMBER**: 0001493152-26-029607

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 11

**CONFORMED PERIOD OF REPORT**: 20260616

**ITEM INFORMATION**: Submission of Matters to a Vote of Security Holders

**FILED AS OF DATE**: 20260622

**DATE AS OF CHANGE**: 20260622

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** GENELUX Corp
- **CENTRAL INDEX KEY:** 0001231457
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-41599
- **FILM NUMBER:** 261107704

**BUSINESS ADDRESS:**
- **STREET 1:** 2625 TOWNSGATE ROAD, SUITE 230
- **CITY:** WESTLAKE VILLAGE
- **STATE:** CA
- **ZIP:** 91361
- **BUSINESS PHONE:** 805-267-9889

**MAIL ADDRESS:**
- **STREET 1:** 2625 TOWNSGATE ROAD, SUITE 230
- **CITY:** WESTLAKE VILLAGE
- **STATE:** CA
- **ZIP:** 91361

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** GENELUX CORP
- **DATE OF NAME CHANGE:** 20030508

?xml version='1.0' encoding='ASCII'?

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT** 

**Pursuant to Section 13 or 15(d)** 

**of the Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): June 16, 2026**

**Genelux Corporation**

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **001-41599** | **77-0583529** |
| **(State or other jurisdiction**<br> **of incorporation)** | **(Commission**<br> **File Number)** | **(I.R.S. Employer**<br> **Identification No.)** |
| **2625 Townsgate Road, Suite 230** <br> **Westlake Village, California** | **2625 Townsgate Road, Suite 230** <br> **Westlake Village, California** | **91361** |
| **(Address of principal executive offices)** | **(Address of principal executive offices)** | **(Zip Code)** |

---

**Registrant's telephone number, including area code: (805) 267-9889**

**Not Applicable** 

**(Former name or former address, if changed since last report.)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
| Common stock, par value $0.001 per share | GNLX | The Nasdaq Stock Market LLC |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

**5.07** **Submission of Matters to a Vote of Security Holders.** 

On June 16, 2026, the Company held its 2026 Annual Meeting of Stockholders (the "*Annual Meeting*"). As of April 17, 2026, the record date for the Annual Meeting (the "*Record Date*"), 44,842,243 shares of the Company's Common Stock were outstanding and entitled to vote at the Annual Meeting. A summary of the matters voted upon by stockholders at the Annual Meeting is set forth below.

A total of 28,263,200 shares of the Company's Common Stock were present at the Annual Meeting in person, by virtual attendance or by proxy, which represents approximately 63.03% of the shares of the Company's Common Stock outstanding as of the Record Date.

***Proposal 1. Election of Directors.***

The Company's stockholders elected the person listed below as the Class I Director, to serve until the Company's 2029 Annual Meeting of Stockholders and until their successor is duly elected and qualified or until their earlier death, resignation or removal. The final voting results are as follows:

---

| | | | |
|:---|:---|:---|:---|
| **Name** | **Votes For** | **Votes Withheld** | **Broker Non-Votes** |
| John Smither | 8696891 | 3393408 | 16172901 |

---

***Proposal 2. Ratification of the Selection of Independent Registered Public Accounting Firm.***

The Company's stockholders ratified the selection of Weinberg & Company, P.A. by the Audit Committee of the Board as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026. The final voting results are as follows:

---

| | | | |
|:---|:---|:---|:---|
| **Votes For** | **Votes Against** | **Abstentions** | **Broker Non-Votes** |
| 28092768 | 105158 | 65274 | 0 |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | **Genelux Corporation** | **Genelux Corporation** |
| Date: June 22, 2026 | By: | */s/ Thomas Zindrick, J.D.* |
|  |  | Thomas Zindrick, J.D. |
|  |  | President and Chief Executive Officer |

---